Cargando…
Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models
Oncolytic virus (OV) as a promising therapeutic agent can selectively infect and kill tumor cells with naturally inherited or engineered properties. Considering the limitations of OVs monotherapy, combination therapy has been widely explored. MEK inhibitor (MEKi) Trametinib is an FDA-approved kinase...
Autores principales: | Zhou, XuSha, Zhao, Jing, Zhang, Jian V., Wu, Yinglin, Wang, Lei, Chen, Xiaoqing, Ji, Dongmei, Zhou, Grace Guoying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473197/ https://www.ncbi.nlm.nih.gov/pubmed/34578339 http://dx.doi.org/10.3390/v13091758 |
Ejemplares similares
-
Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models
por: Wu, Yinglin, et al.
Publicado: (2022) -
Degradation of Herpes Simplex Virus-1 Viral miRNA H11 by Vaccinia Virus Protein VP55 Attenuates Viral Replication
por: Zou, Weixuan, et al.
Publicado: (2020) -
High accumulation of Mx2 renders limited multiplication of oncolytic herpes simplex virus-1 in human tumor cells
por: Ren, Yong, et al.
Publicado: (2021) -
Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022) -
Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)